Cargando…

Pregnancy in sickle cell disease – do we know what to expect?()

Detalles Bibliográficos
Autor principal:	Fertrin, Kleber Yotsumoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2014
Materias:	Scientific Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318377/ https://www.ncbi.nlm.nih.gov/pubmed/25305160 http://dx.doi.org/10.1016/j.bjhh.2014.07.017

Ejemplares similares

It is never too late to rethink serum folate()
por: Fertrin, Kleber Yotsumoto
Publicado: (2018)

Compound heterozygosity for hemoglobin S and D: what do we need to know?()
por: Bonini-Domingos, Claudia Regina
Publicado: (2016)

Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia
por: Claudino, Mário Angelo, et al.
Publicado: (2012)

COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020)

Cancer and COVID-19: what do we really know?
por: Poortmans, Philip M, et al.
Publicado: (2020)

Sexuality and sickle cell disease
por: Figueiredo, Maria Stella
Publicado: (2013)

Is sickle cell disease the same everywhere?
por: Hankins, Jane
Publicado: (2012)

Oxidative stress in sickle cell disease
por: Queiroz, Raphael Ferreira, et al.
Publicado: (2013)

Comments on renal abnormalities of sickle cell disease
por: Abbud-Filho, Mario
Publicado: (2013)

ABO isohemagglutinin titration or hemolysin test: what should we do to reduce the risk of passive hemolysis?()
por: Castilho, Lilian
Publicado: (2015)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Sickle cell disease: looking back but towards the future
por: Cançado, Rodolfo Delfini
Publicado: (2012)

Comment on sickle cell disease and left ventricular hypertrophy()
por: Verissimo, Monica Pinheiro de Almeida
Publicado: (2015)

Neuropsychiatric Consequences of COVID-19: What Do We Know So Far?
por: Machado, Sergio, et al.
Publicado: (2022)

An eye on sickle cell retinopathy()
por: de Melo, Mônica Barbosa
Publicado: (2014)

Dynamics of sickle cell disease as one of the determinants of quality of life
por: Ivo, Maria Lúcia, et al.
Publicado: (2013)

Oxidative status in sickle cell anemia
por: Magalhães, Silvia Maria Meira
Publicado: (2011)

Comprehensive healthcare for individuals with sickle cell disease - a constant challenge
por: Cançado, Rodolfo Delfini
Publicado: (2011)

Do we know the limits of the heart?
por: Figueras-Coll, Marc, et al.
Publicado: (2022)

Offline: COVID-19—what we can expect to come
por: Horton, Richard
Publicado: (2020)

The COVID-19 pandemic in the USA: what might we expect?
por: Chowell, Gerardo, et al.
Publicado: (2020)

Sickle cell disease: from the beginning until it was recognized as a public health disease
por: Naoum, Paulo Cesar
Publicado: (2011)

Arterial Stiffness—What Do We Know about It and What Do We Expect from This Biomarker?
por: Reiner, Željko
Publicado: (2022)

The invisibility of sickle cell disease in Brazil: lessons from a study in Maranhão()
por: Viana, Marcos Borato
Publicado: (2015)

What do we do and how do we do it? Assessing genetic counselling in the modern era
por: Yeates, Laura, et al.
Publicado: (2020)

Nitric oxide status in sickle cell anemia
por: Gonçalves, Romélia Pinheiro
Publicado: (2012)

Open Questions: We don’t really know anything, do we? Open questions in sensory biology
por: Johnsen, Sönke
Publicado: (2017)

Comment on: “Oral health-related quality of life in children and teens with sickle cell disease”()
por: Correa, Maria Elvira Pizzigatti
Publicado: (2016)

Sex differences in COVID-19 case fatality: do we know enough?
por: Dehingia, Nabamallika, et al.
Publicado: (2021)

Fetal hemoglobin and hemolysis markers in sickle cell anemia()
por: Colella, Marina Pereira, et al.
Publicado: (2015)

What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 Omicron variant?
por: Scendoni, Roberto, et al.
Publicado: (2023)

Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
por: Ong, Albert C M, et al.
Publicado: (2022)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Tight glycemic control: what do we really know, and what should we expect?
por: Nasraway, Stanley A, et al.
Publicado: (2010)

Comments on: molecular matching of red blood cells is superior to serological matching in sickle cell disease patients
por: Nance, Sandra Taddie, et al.
Publicado: (2013)

Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know?
por: Vehbi, Sezan, et al.
Publicado: (2022)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Sickle cell anemia: clinical diversity and beta S-globin haplotypes
por: Loggetto, Sandra Regina
Publicado: (2013)

Haptoglobin: an emerging candidate for phenotypic modulation of sickle cell anemia?()
por: Santos, Magnun Nueldo Nunes dos
Publicado: (2015)

What do medical students actually need to know about artificial intelligence?
por: McCoy, Liam G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hvisjdbmitqmtj0l3ne4ar8le2